Do People With Tophaceous Gout Require More Allopurinol for Good Clinical Outcomes? Analysis of 2 Randomized Controlled Trials of Allopurinol Dose Escalation
Authors' conclusion
Despite the higher monosodium urate crystal burden in those with tophi, key gout outcomes, including urate-lowering efficacy and absence of gout flares, did not differ from those without tophi when allopurinol was prescribed.
Study context
- Population
- People with gout in 2 randomised trials of allopurinol dose escalation; mostly male, European ethnicity, longstanding gout; tophi in 33%
- Participants
- 383 people2 RCTs
- Comparison
- Participants with vs without baseline tophi during 1 year of allopurinol prescribed to an serum urate (SU) target
- Outcome
- Target-level SU
- Follow-up
- 12 months
Methodological detailstreat-to-target allopurinol, SU target < 0.36 mmol/L, Cochran-Mantel-Haenszel test, controlling for study
- Treat-to-target allopurinol
- SU target < 0.36 mmol/L
- Cochran-Mantel-Haenszel test, controlling for study
Pooled result
As reported in the abstract
P = 0.76
Further pooled results
No gout flares during the month before month 12 · no statistically significant difference
P = 0.27
Original publication
Do People With Tophaceous Gout Require More Allopurinol for Good Clinical Outcomes? Analysis of 2 Randomized Controlled Trials of Allopurinol Dose Escalation. J Rheumatol. Published 15 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →